Can the further clinical development of bevirimat be justified?
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Infectious Diseases,Immunology,Immunology and Allergy
Reference8 articles.
1. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-O-(3′,3′-dimethylsuccinyl) betulinic acid (bevirimat) against human immunodeficiency virus infection;Smith;Antimicrob Agents Chemother,2007
2. Inhibition of HIV-1 maturation via drug association with the viral Gag protein in immature HIV-1 particles;Zhou;J Biol Chem,2005
3. Human immunodeficiency virus type 1 resistance to the small molecule maturation inhibitor 3-O-(3′,3′-dimethylsuccinyl)-betulinic acid is conferred by a variety of single amino acid substitutions at the CA-SP1 cleavage site in Gag;Zhou;J Virol,2006
4. Maturation inhibitors: a new therapeutic class targets the virus structure;Salzwedel;AIDS Rev,2007
5. Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients;Malet;AIDS,2007
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Sub-stoichiometric Modulation of Viral Targets─Potent Antiviral Agents That Exploit Target Vulnerability;ACS Medicinal Chemistry Letters;2023-07-11
2. Strategies to overcome HIV drug resistance-current and future perspectives;Frontiers in Microbiology;2023-02-16
3. The Discovery of GSK3640254, a Next-Generation Inhibitor of HIV-1 Maturation;Journal of Medicinal Chemistry;2022-08-31
4. A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants;Antimicrobial Agents and Chemotherapy;2021-05-18
5. Phase I evaluation of pharmacokinetics and tolerability of the HIV‐1 maturation inhibitor GSK3640254 and dolutegravir in healthy adults;British Journal of Clinical Pharmacology;2021-03-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3